dc.contributor.author | TAJBER, LIDIA | en |
dc.contributor.author | EHRHARDT, CARSTEN | en |
dc.contributor.author | PALUCH, KRZYSZTOF | en |
dc.contributor.author | HEALY, ANNE | en |
dc.date.accessioned | 2013-09-03T15:50:53Z | |
dc.date.available | 2013-09-03T15:50:53Z | |
dc.date.issued | 2013 | en |
dc.date.submitted | 2013 | en |
dc.identifier.citation | Tewes F, Paluch KJ, Tajber L, Gulati K, Kalantri D, Ehrhardt C, Healy AM, Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery, European Journal of Pharmaceutics and Biopharmaceutics, 85, 3, 2013, 604 - 613 | en |
dc.identifier.other | Y | en |
dc.description | PUBLISHED | en |
dc.description.abstract | In a number of pulmonary diseases, patients may develop abnormally viscous mucus reducing drug efficacy. To increase budesonide diffusion within lung fluid, we developed nanoporous microparticles (NPMPs) composed of budesonide and a mucokinetic, ambroxol hydrochloride, to be inhaled as a dry powder. Budesonide/ambroxol-HCl particles were formulated by spray drying and characterised by various physicochemicals methods. Aerodynamic properties were evaluated using a cascade impactor. Drugs apparent permeability coefficients were calculated across mucus producing Calu-3 cell monolayers cultivated at an air?liquid interface. Microparticles made only from budesonide and ambroxol-HCl had smooth surfaces. In the presence of ammonium carbonate ((NH4)2CO3), NPMPs were formulated, with significantly (P < 0.05) superior aerodynamic properties (MMAD = 1.87 ? 0.22 ?m and FPF = 84.0 ? 2.6%). The formation of nanopores and the increase in the specific surface area in the presence of (NH4)2CO3 were mainly attributed to the neutralisation of ambroxol-HCl to form ambroxol base. Thus, ambroxol base could behave in the same manner as budesonide and prompt nanoprecipitation when spray dried from an ethanol/water mix occurs. All formulations were amorphous, which should enhance dissolution rate and diffusion through lung fluid. These NPMPs were able to improve budesonide permeability across mucus producing Calu-3 cell monolayers (P < 0.05) suggesting that they should be able to enhance budesonide diffusion in the lungs through viscous mucus | en |
dc.format.extent | 604 | en |
dc.format.extent | 613 | en |
dc.language.iso | en | en |
dc.relation.ispartofseries | European Journal of Pharmaceutics and Biopharmaceutics | en |
dc.relation.ispartofseries | 85 | en |
dc.relation.ispartofseries | 3 | en |
dc.rights | Y | en |
dc.subject.other | Budesonide | |
dc.title | Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery | en |
dc.type | Journal Article | en |
dc.type.supercollection | scholarly_publications | en |
dc.type.supercollection | refereed_publications | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/ehrhardc | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/healyam | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/ltajber | en |
dc.identifier.rssinternalid | 84289 | en |
dc.identifier.doi | 10.1016/j.ejpb.2013.03.020 | en |
dc.rights.ecaccessrights | OpenAccess | |
dc.subject.TCDTheme | Immunology, Inflammation & Infection | en |
dc.subject.TCDTheme | Nanoscience & Materials | en |
dc.identifier.orcid_id | 0000-0003-0730-1829 | en |
dc.contributor.sponsor | Science Foundation Ireland (SFI) | en |
dc.identifier.uri | http://hdl.handle.net/2262/67347 | |